



July 3, 2026

National Stock Exchange of India Limited
Exchange Plaza, Bandra-Kurla Complex,
Bandra (E), Mumbai - 400 051, Maharashtra.

BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001, Maharashtra.

Symbol: STAR

Scrip Code: 532531

Dear Madam/ Sir,

Ref: Press Release issued by the Company on June 27, 2026 titled “Strides Partners with Ascent Capital to Unlock Value in Pivot Path” and the disclosure made under Regulation 30 of SEBI Listing Regulations.

Sub: Update on completion of transaction relating to Pivot Path

With reference to the above, we wish to inform you that the transaction pertaining to Strides’ partnership with Ascent Capital for unlocking value in Pivot Path has been successfully completed.

As previously disclosed, the transaction involved sale of Strides’ majority stake in Pivot Path to a consortium led by Ascent Capital, together with co-investor Vintage Classic, for an aggregate consideration of approximately ₹1,000 million.

Pursuant to completion of the transaction, the Company has received ₹750 million, with the balance consideration of ₹250 million being payable on the first anniversary of the closing date, in accordance with the agreed transaction terms.

Consequent to the completion of the transaction, Pivot Path has ceased to be a Wholly Owned Subsidiary of the Company with effect from July 1, 2026 and shall henceforth be classified as an Associate Company.

Kindly take the above information on record.

Thanks & Regards,

For **Strides Pharma Science Limited**,

Manjula Ramamurthy
Company Secretary & Compliance Officer
ICSI Membership No. A30515

Strides Pharma Science Limited

CIN: L24230MH1990PLC057062

Corp. Off: Strides House, Bilekahalli, Bannerghatta Road, Bengaluru – 560 076, India | **Tel:** +91 80 6784 0000

Regd. Off: ‘Cyber One’, Unit No. 902, Plot No. 4&6, Sector 30A, Vashi, Navi Mumbai – 400 703, India

Tel: +91 22 2789 2924/3199

corpcomm@strides.com; www.strides.com